Antibody-drug conjugates and the link to fighting cancer

Since the approval of the first antibody-drug conjugate (ADC) in 2000, ADCs have become a massive  focus in the oncology sector. This is due to the fact that they are able to combine highly specific targeting with a potent cytotoxic payload to deliver exceptional results.

But how have they been so successful where small molecules haven’t? Abzena’s Chief Scientific Officer, Dr Campbell Bunce,  shares his thoughts in IPI Autumn 2023 issue. Read more on pages 28-31.